<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> AND <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> TOXOIDS ADSORBED- clostridium tetani toxoid antigen (formaldehyde inactivated) and corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) injection </strong><br>Akorn, Inc.<br></p></div>
<h1><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> AND <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> TOXOIDS ADSORBED</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed (Td) manufactured by MassBiologics is a sterile vaccine for intramuscular injection.  After <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, the vaccine appears as a homogeneous milky white suspension.<br><br>Each 0.5 ml dose of MassBiologics' Td is formulated to contain the following active ingredients: 2 Lf of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and 2 Lf of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid.  Each 0.5 ml dose also contains aluminum adjuvant (not more than 0.53 mg aluminum by assay), &lt; 100 mcg (0.02%) of residual formaldehyde, and a trace amount of thimerosal [mercury derivative, (≤ 0.3 mcg mercury/dose)] (not as a preservative) from the manufacturing process.<br><br>The<span class="Italics"> Corynebacterium diphtheriae</span> and <span class="Italics">Clostridium tetani</span>  organisms are grown on modified Mueller's media<span class="Sup">1,2</span> which contains bovine extracts.  The bovine material used in these extracts is sourced from countries which the United States Department of Agriculture has determined neither have nor present an undue risk for bovine spongiform <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.  <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxins produced during growth of the cultures are detoxified with formaldehyde.  The detoxified materials are then separately purified by ammonium sulfate fractionation.  The <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid is further purified by column chromatography.  The <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids are individually adsorbed onto aluminum phosphate.<br><br>The <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids induce at least 2 units and 1 unit of antitoxin per ml of serum, respectively, in the guinea pig potency test.<br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span><br><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> (also known as <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">lockjaw</span>) is a serious, often fatal disease caused by an extremely potent neurotoxin produced by<span class="Italics"> C. tetani.</span>  <br><br>Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin.  A serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin level of 0.01 IU/ml measured via a neutralization assay is considered the minimum protective level.<span class="Sup">3,4</span>  The efficacy against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> of MassBiologics' Td is supported by the following:<br><br>1.  Response to primary series.  Of 20 adults with less than 0.0025 units/ml of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin in pre-immunization serum, 14 (70%) had antitoxin concentrations of 0.01 or greater after 2 doses of Td (2 Lf <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid dose).  After 3 doses of Td, 16 of 16 adults achieved 0.01 antitoxin units/ml.<br><br>2.  Response to booster doses.  Booster doses of Td at doses of 1 Lf and 5 Lf of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid induced <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels greater than 0.01 units/ml when administered to all 36 adults who had received prior <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immunizations.<span class="Sup">5</span><br><br><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span><br><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> is an acute toxin-mediated disease caused by toxigenic <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> C. diphtheriae. </span>Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxin.  A serum <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin level of 0.01 IU/ml is the lowest level giving some degree of protection.<span class="Sup">3,6</span>  The efficacy against <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> of MassBiologics' Td is supported by the following:<br><br>1.  Response to primary series.  Of 10 adults with less than 0.001 units/ml of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> antitoxin in pre-immunization serum, 50% had antitoxin concentrations of 0.01 or greater after 2 doses of Td (2 Lf <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid dose).  After 3 doses of Td, 6 of 6 adults achieved 0.01 antitoxin units/ml.<br><br>2.  Response to booster doses.  In clinical trials, booster doses of Td formulated to contain 1 Lf and 5 Lf of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid, both induced antitoxin levels greater than 0.01 units/ml when administered to adults with prior <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> immunity.<span class="Sup">5,7,8</span>  In 140 adolescent males given a single booster dose of the 1 Lf formulation, all achieved an antitoxin titer of 0.01 units/ml or higher.<span class="Sup">8</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MassBiologics' Td is a vaccine indicated for active immunization for the prevention of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>.  This vaccine is approved for use in persons 7 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">A severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) occurring after a previous dose of this vaccine, or any other <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid-containing vaccine, or any component of this vaccine is a contraindication to administration of MassBiologics’ Td vaccine.  (See <span class="Bold">DESCRIPTION</span>).  Because of the uncertainty as to which component of the vaccine might be responsible, no further vaccination with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> components should be carried out.  Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">FREQUENCY OF ADMINISTRATION<br>More frequent administration of MassBiologics' Td than described in <span class="Bold">DOSAGE AND ADMINISTRATION </span>may be associated with an increased incidence and severity of adverse reactions.</p>
<p>ARTHUS REACTIONS<br>Persons who experienced an Arthus-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> following a prior dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine usually have high serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels and should not receive MassBiologics' Td more frequently than every 10 years, even for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> prophylaxis as part of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management. (See  <span class="Bold">DOSAGE AND ADMINISTRATION</span>).</p>
<p>GUILLAIN-BARRÉ SYNDROME<br>A review by the Institute of Medicine found evidence for a causal relation between <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and Guillain-Barré Syndrome.<span class="Sup">9</span>  If Guillain-Barré Syndrome occurred within 6 weeks after receipt of a previous dose of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, the decision to give subsequent doses of MassBiologics' Td or any vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid should be based on careful consideration of the potential benefits and possible risks.<span class="Sup">10</span></p>
<p><br>Vaccination with MassBiologics' Td may not protect all individuals.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">GENERAL<br>Epinephrine injection (1:1000) and other appropriate agents and equipment must be immediately available should an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylactic reaction</span> occur.<br><br>Prior to the administration of MassBiologics' Td, the vaccine recipient's current health status and health history should be reviewed.  This includes a review of the immunization history of the patient, the presence of any contraindications to immunization, and any adverse events after previous immunizations to allow an assessment of the benefits and risks of vaccination.  (See<span class="Bold"> CONTRAINDICATIONS</span> and<span class="Bold"><span class="Bold"> WARNINGS</span></span>)<span class="Bold"><span class="Bold"><span class="Bold">.</span></span></span></p>
<p><span class="Bold"><span class="Bold"><span class="Bold"></span></span></span>If MassBiologics' Td is administered to immunocompromised persons (whether from disease or treatment) the expected immune response may not be obtained.<br><br>INFORMATION FOR PATIENTS<br>Prior to administration of MassBiologics' Td, patients, parents or guardians should be informed by the health care provider of the benefits and risks of immunization with Td and of the importance of completing the primary immunization series or receiving recommended booster doses.<br><br>The health care provider should inform the patient, parent, or guardian of the potential for adverse reactions that have been temporally associated with MassBiologics' Td or other vaccines containing similar ingredients.  Patients, parents or guardians should be instructed to report any suspected adverse reactions to their health care provider.<br><br>According to the National Childhood Vaccine Injury Act of 1986, Vaccine Information Statements must be provided by the health care provider with each vaccine dose administered.<span class="Sup">10</span><br><br>DRUG INTERACTIONS<br>Patients who are on immunosuppressive therapy, including alkylating agents, antimetabolites, cytotoxic drugs, irradiation, or corticosteroids (used in greater than physiologic doses), may have a reduced immune response to vaccines.<br><br>No safety and immunogenicity data are available on the concomitant administration of MassBiologics' Td vaccine with other U.S. licensed vaccines.<br><br>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY<br>No studies have been performed with MassBiologics' Td to evaluate carcinogenicity, mutagenic potential, or impairment of fertility.<br><br>PREGNANCY CATEGORY C<br>Animal reproduction studies have not been conducted with MassBiologics' Td.  It is also not known whether MassBiologics' Td can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  MassBiologics' Td should be given to a pregnant woman only if clearly needed.<br><br>NURSING MOTHERS<br>It is not known whether MassBiologics' Td is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when MassBiologics' Td is administered to a nursing woman.<br><br>PEDIATRIC USE<br>MassBiologics' Td is not approved for use in infants and children younger than 7 years of age.  The safety and effectiveness of MassBiologics' Td in this age group have not been established.<br><br>GERIATRIC USE<br>No studies have been performed with MassBiologics' Td in adults aged 65 years and older in order to determine whether they respond differently than younger subjects.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">DATA FROM CLINICAL TRIALS<br>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine, and may not reflect the rates observed in practice.  However, the adverse reaction information from clinical trials provides a basis for identifying adverse events that appear to be related to vaccine use and for approximating rates.  Data on adverse reactions following fluid and adsorbed preparations of MassBiologics' Td with various doses of the <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> components have been reported in a series of studies.<span class="Sup">5,7,8,11,12</span></p>
<p>POSTMARKETING REPORTS<br>The following adverse events have been identified during post-approval use of MassBiologics' Td.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequencies or to establish a causal relationship to vaccination.  The following adverse events were included because of seriousness or frequency of reporting:</p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>, including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, pruritis, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and warmth; <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral oedema</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span>  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span></p>
<p>REPORTING OF SUSPECTED ADVERSE REACTIONS<span class="Bold"><br>To report SUSPECTED ADVERSE REACTIONS, contact MassBiologics at 1-800-457-4626 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">PRIMARY IMMUNIZATION<br>MassBiologics' Td may be used in persons 7 years of age and older who have not been previously immunized against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, as a primary immunization series consisting of three 0.5 ml doses.  The first two doses are administered 4-8 weeks apart and the third dose is administered 6-12 months after the second dose.</p>
<p>MassBiologics'  Td may be used to complete the primary immunization series for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, following one or two doses of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (whole cell DTP), <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (DTaP) and/or <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed (DT) vaccine.  However, the safety and efficacy of MassBiologics' Td in such regimens have not been evaluated.</p>
<p>ROUTINE BOOSTER IMMUNIZATION<br>MassBiologics' Td may be used for routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> in persons 7 years of age and older who have completed primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>.  Routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> is recommended in children 11-12 years of age and every 10 years thereafter.<span class="Sup">10</span></p>
<p>The Advisory Committee on Immunization Practices (ACIP) has specific recommendations on booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> for adolescents and adults.<span class="Sup">10,13,14</span></p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT <br>For active <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> immunization in <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management of patients 7 years of age and older, a preparation containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids is preferred instead of single-antigen <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid to enhance <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> protection.<span class="Sup">15</span> MassBiologics' Td is approved for <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management of patients 7 years of age and older.    </p>
<p>The need for active immunization with a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparation, with or without <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (TIG) (Human) depends on both the condition of the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> and the patient's vaccination history (Table 1).</p>
<p>When indicated, TIG (Human) should be administered using a separate needle and syringe at a different anatomic site, according to the manufacturer's package insert.  If a contraindication to using a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine exists in a person who has not completed <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> primary immunization and other than a clean, minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> is sustained, only passive immunization with TIG (Human) should be given.<span class="Sup">15</span></p>
<p>TABLE 1  GUIDE TO <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN ROUTINE <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT IN PERSONS AGED 7 YEARS AND OLDER <span class="Sup">13,14,15</span></p>
<a name="i92b3d3a9-6472-44e3-8c59-a7855f2506f1"></a><table border="1" width="100%"><tbody class="Headless">
<tr class="First">
<td align="center" colspan="1" rowspan="2">
<span class="Bold">History of Adsorbed <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid (Doses)</span><br>
</td>
<td align="center" colspan="2">
<span class="Bold">Clean, Minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span></span><br>
</td>
<td align="center" colspan="2">
<span class="Bold">All Other <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span>*</span><br>
</td>
</tr>
<tr>
<td align="center">Td†<br>
</td>
<td align="center">TIG<br>
</td>
<td align="center">Td†<br>
</td>
<td align="center">TIG<br>
</td>
</tr>
<tr>
<td align="center">Unknown or &lt; 3<br>
</td>
<td align="center">Yes<br>
</td>
<td align="center">No<br>
</td>
<td align="center">Yes<br>
</td>
<td align="center">Yes<br>
</td>
</tr>
<tr class="Last">
<td align="center">≥ 3 ‡<br>
</td>
<td align="center">No§<br>
</td>
<td align="center">No<br>
</td>
<td align="center">No¶<br>
</td>
<td align="center">No<br>
</td>
</tr>
</tbody></table>
<p>* Such as, but not limited to, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> contaminated with dirt, feces, soil, and saliva; puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>; avulsions; and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> resulting from missiles, crushing, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> and <span class="product-label-link" type="condition" conceptid="441487" conceptname="Frostbite">frostbite</span>.<br>† The ACIP has specific recommendations on use of Td or <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid, Reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (Tdap) in adolescents and adults.<span class="Sup">13,14</span><br>‡ If only three doses of fluid <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid have been received, then a fourth dose of toxoid, preferably an adsorbed toxoid, should be given.<br>§ Yes, if ≥ 10 years since the last <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine dose.<br>¶ Yes, if ≥ 5 years since the last <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine dose.  (More frequent boosters are not needed and can accentuate side effects.)</p>
<p><span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> PROPHYLAXIS FOR CASE CONTACTS<br>MassBiologics' Td may be used for post-exposure <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> prophylaxis in persons 7 years of age and older who have not completed primary vaccination, whose vaccination status is unknown, or who have not been vaccinated with <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid within the previous 5 years.  Consult ACIP recommendations for additional interventions for post-exposure <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> prophylaxis.<span class="Sup">15</span></p>
<p>ADMINISTRATION<br>Shake the vial well to resuspend the vaccine before withdrawing the dose.  After <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, MassBiologics' Td is a homogenous milky white suspension.  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  If these conditions exist, MassBiologics' Td should not be administered.</p>
<p>Inject 0.5 ml of MassBiologics' Td intramuscularly.  The preferred site is the deltoid muscle.  The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.</p>
<p>Do not administer this vaccine intravenously, subcutaneously, or intradermally.</p>
<p>MassBiologics' Td should not be combined through reconstitution or mixed with any other vaccine.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">The stopper of the vial is latex free.<br>MassBiologics’ Td is supplied in a package of 10 single dose vials.<br>NDC No. 17478-131-00 is the code for individual single dose (0.5ml) vials.<br>NDC No. 17478-131-01 is the code for the package containing ten vials.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store at 2°C - 8°C (36°F - 46°F).  DO NOT FREEZE.  Discard product if exposed to freezing.<br><br>Do not use vaccine after expiration date.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. Latham WC, Bent DF, and Levine L. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxin production in the absence of protein. Appl. Microbiol. 10(2): March 1962;146-152.</p>
<p>2. Mueller JH and Miller PA. Production of diphtheric toxin of high potency (100 Lf) on a reproducible medium. J. Immunol. 40: 1941;21-32.</p>
<p>3. Food and Drug Administration. Department of Health and Human Services (DHHS). Biological Products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. Fed Reg 1985;50(240): 51002-117.</p>
<p>4. Wassilak SGF, et al. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5<span class="Sup">th</span> ed. Philadelphia, PA: WB Saunders Company; 2008. p. 805-839.</p>
<p>5. Ipsen J. Jr. Immunization of adults against <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. NEJM. 1954; 251:459-466</p>
<p>6. Vitek CR and Wharton M. <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> toxoid. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5<span class="Sup">th</span> ed. Philadelphia, PA: WB Saunders Company; 2008. p. 139-156.</p>
<p>7. Edsall G, Altman JS, and Gaspar AJ. Combined <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-<span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> immunization of adults: Use of small doses of <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid. Am J Public Health Nations Health. 1954 Dec;44(12):1537-1545.</p>
<p>8. Levine L, Ipsen J, and McComb JA. Adult immunization: preparation and evaluation of combined fluid <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids for adult use. Am. J. Hyg. 1961;73:20-35.</p>
<p>9. Institute of Medicine. Stratton KR, et al, eds. <span class="Italics">Adverse Events Associated with Childhood Vaccines:</span><span class="Italics"> Evidence Bearing on Casuality.</span> Washington D.C.: National Academy Press. 1994:67-117.</p>
<p>10. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-15):1-48.</p>
<p>11. McComb JA and Levine L. Adult immunization II. Dosage reduction as a solution to increasing reactions to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid. NEJM. 1961;256:1152-1158.</p>
<p>12. Levine L and Edsall G. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> toxoid: What determines reaction proneness? J. Infect. Dis. 1981;144:376.</p>
<p>13. Centers for Disease Control and Prevention. Preventing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> among adolescents: use of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid and acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3):1-43.</p>
<p>14. Centers for Disease Control and Prevention. Preventing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> among adults: use of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, reduced <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid and acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR 2006;55(No. RR-17):1-37.</p>
<p>15. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP). <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span>: recommendations for vaccine use and other preventive measures. MMWR 1991;40(No. RR-10):1-35.</p>
<p>Manufactured by:<br>MassBiologics<br>University of Massachusetts Medical School<br>Boston, MA 02130<br>US Government License No. 1779</p>
<p><br>Distributed by:<br>Akorn, Inc.<br>Lake Forest, IL 60045<br><br><br>Product information as of August 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Carton Label</h1>
<div class="Figure"><img alt="Td Carton C0140" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22b5a944-422f-4a18-a04d-6bacd5612ae6&amp;name=TdCarton_C0140.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>Vial Label</h1>
<div class="Figure"><img alt="Td Vial label L0142" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=22b5a944-422f-4a18-a04d-6bacd5612ae6&amp;name=L0142_Td%20vial.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> AND <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">DIPHTHERIA</span> TOXOIDS ADSORBED 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoids adsorbed injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-131</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">2.0 [Lf]  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">2.0 [Lf]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM PHOSPHATE</strong></td>
<td class="formItem">0.53 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FORMALDEHYDE</strong></td>
<td class="formItem">100 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>THIMEROSAL</strong></td>
<td class="formItem">0.3 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (after <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, the vaccine appears as a homogenous milky white suspension) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-131-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-131-00</td>
<td class="formItem">0.5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA101322</td>
<td class="formItem">07/27/1970</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>MassBiologics (019081961)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MassBiologics</td>
<td class="formItem"></td>
<td class="formItem">019081961</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d8a5748-ec3d-4a1b-a7b1-ce54ba397a30</div>
<div>Set id: 22b5a944-422f-4a18-a04d-6bacd5612ae6</div>
<div>Version: 2</div>
<div>Effective Time: 20140501</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
